Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux® (cetuximab) product information, updating the indication for Erbitux to the ...
Laboratory Corporation of America Holdings (LabCorp) has announced the nationwide availability of QIAGEN’s therascreen KRAS RGQ PCR kit, a new US Food and Drug Administration (FDA) approved companion diagnostic for certain colorectal ...
Tags: Labcorp, Colorectal Cancer
Oncobiologics and inVentiv Health have formed a global, strategic partnership for clinical development of biosimilar assets initially with a probable expansion to new molecules. The biosimilar assets include generic versions of Humira, ...
Tags: Oncobiologics, Biosimilars
Qiagen has won the US Food and Drug Administration (FDA) approval for its new molecular companion diagnostic product, therascreen KRAS RGQ PCR test kit, to provide guidance on the use of Erbitux for approximately 110,000 US patients with ...
Tags: Qiagen, FDA, molecular companion diagnostic product, test kit
Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) have received an approval from US Food and Drug Administration (FDA) to expand the use of Erbitux in combination with the chemotherapy regimen Folfiri as an initial treatment of patients with ...
Tags: FDA approval, Erbitux, KRAS mutation-negative colorectal cancer